{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:16:17Z","timestamp":1784664977076,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","award":["201000614"],"award-info":[{"award-number":["201000614"]}],"id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 77645"],"award-info":[{"award-number":["MOP 77645"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Classical Hodgkin Lymphoma (cHL) is primarily a B cell lymphoid neoplasm and a member of the CD30\u2013positive lymphomas. cHL and the other CD30\u2013positive lymphomas are characterized by the elevated expression and\/or constitutive activation of the activator protein-1 (AP-1) family transcription factors, c-Jun and JunB; however, the specific roles they play in the pathobiology of cHL are unclear. In this report we show that reducing either c-Jun or JunB expression with short-hairpin RNAs (shRNAs) reduced the growth of cHL cell lines <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, primarily through impairing cell cycle transition through G<jats:sub>1<\/jats:sub>. We further investigated the effect of c-Jun and JunB knock-down on proliferation in another CD30\u2013positive lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL). We found that JunB knock-down in most ALK+ ALCL cell lines examined also resulted in reduced proliferation that was associated with a G<jats:sub>0<\/jats:sub>\/G<jats:sub>1<\/jats:sub> cell cycle defect. In contrast, c-Jun knock-down in multiple ALK+ ALCL cell lines had no effect on proliferation. In summary, this study directly establishes that both c-Jun and JunB play roles in promoting HRS cell proliferation. Furthermore, we demonstrate there are similarities and differences in c-Jun and JunB function between cHL and ALK+ ALCL.<\/jats:p>","DOI":"10.1038\/s41598-018-34199-9","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T11:03:31Z","timestamp":1540379011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The c-Jun and JunB transcription factors facilitate the transit of classical Hodgkin lymphoma tumour cells through G1"],"prefix":"10.1038","volume":"8","author":[{"given":"Jingxi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoqiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Savin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Han R.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeniu","family":"Jantuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julinor T. C.","family":"Bacani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Ingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"34199_CR1","unstructured":"Stein, H. et al. In WHO Series on Histological and Genetic Typing of Human Tumours (ed Campo E. et al.) (International Agency for Research on Cancer (IARC), 2008)."},{"key":"34199_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","volume":"53","author":"S Mathas","year":"2016","unstructured":"Mathas, S., Hartmann, S. & Kuppers, R. Hodgkin lymphoma: Pathology and biology. Seminars in hematology 53, 139\u2013147, https:\/\/doi.org\/10.1053\/j.seminhematol.2016.05.007 (2016).","journal-title":"Seminars in hematology"},{"key":"34199_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s11899-016-0345-y","volume":"11","author":"G Bhatt","year":"2016","unstructured":"Bhatt, G., Maddocks, K. & Christian, B. CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas. Current hematologic malignancy reports 11, 480\u2013491, https:\/\/doi.org\/10.1007\/s11899-016-0345-y (2016).","journal-title":"Current hematologic malignancy reports"},{"key":"34199_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3324\/haematol.2010.029256","volume":"95","author":"L de Leval","year":"2010","unstructured":"de Leval, L. & Gaulard, P. CD30+ lymphoproliferative disorders. Haematologica 95, 1627\u20131630, https:\/\/doi.org\/10.3324\/haematol.2010.029256 (2010).","journal-title":"Haematologica"},{"key":"34199_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","volume":"24","author":"Y Liu","year":"2014","unstructured":"Liu, Y., Sattarzadeh, A., Diepstra, A., Visser, L. & van den Berg, A. The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component. Seminars in cancer biology 24, 15\u201322, https:\/\/doi.org\/10.1016\/j.semcancer.2013.07.002 (2014).","journal-title":"Seminars in cancer biology"},{"key":"34199_CR6","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1182\/blood.V87.10.4340.bloodjournal87104340","volume":"87","author":"RC Bargou","year":"1996","unstructured":"Bargou, R. C. et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin\/Reed-Sternberg cells. Blood 87, 4340\u20134347 (1996).","journal-title":"Blood"},{"key":"34199_CR7","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1172\/JCI119849","volume":"100","author":"RC Bargou","year":"1997","unstructured":"Bargou, R. C. et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin\u2019s disease tumor cells. The Journal of clinical investigation 100, 2961\u20132969, https:\/\/doi.org\/10.1172\/JCI119849 (1997).","journal-title":"The Journal of clinical investigation"},{"key":"34199_CR8","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1182\/blood.V98.3.762","volume":"98","author":"D Kube","year":"2001","unstructured":"Kube, D. et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98, 762\u2013770 (2001).","journal-title":"Blood"},{"key":"34199_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1182\/blood.V99.2.618","volume":"99","author":"BF Skinnider","year":"2002","unstructured":"Skinnider, B. F. et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99, 618\u2013626 (2002).","journal-title":"Blood"},{"key":"34199_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0002-9440(10)62238-9","volume":"166","author":"C Atayar","year":"2005","unstructured":"Atayar, C. et al. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 166, 127\u2013134, https:\/\/doi.org\/10.1016\/S0002-9440(10)62238-9 (2005).","journal-title":"Am J Pathol"},{"key":"34199_CR11","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1182\/blood-2010-01-265827","volume":"116","author":"J Stanelle","year":"2010","unstructured":"Stanelle, J., Doring, C., Hansmann, M. L. & Kuppers, R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed\/Sternberg cells. Blood 116, 4202\u20134211, https:\/\/doi.org\/10.1182\/blood-2010-01-265827 (2010).","journal-title":"Blood"},{"key":"34199_CR12","doi-asserted-by":"publisher","first-page":"E4513","DOI":"10.1073\/pnas.1406985111","volume":"111","author":"S Kreher","year":"2014","unstructured":"Kreher, S. et al. Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 111, E4513\u20134522, https:\/\/doi.org\/10.1073\/pnas.1406985111 (2014).","journal-title":"Proc Natl Acad Sci USA"},{"key":"34199_CR13","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0002-9440(10)63027-1","volume":"159","author":"E Torlakovic","year":"2001","unstructured":"Torlakovic, E., Tierens, A., Dang, H. D. & Delabie, J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin\u2019s disease. Am J Pathol 159, 1807\u20131814, https:\/\/doi.org\/10.1016\/S0002-9440(10)63027-1 (2001).","journal-title":"Am J Pathol"},{"key":"34199_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1182\/blood-2012-05-431429","volume":"121","author":"H Yuki","year":"2013","unstructured":"Yuki, H. et al. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells. Blood 121, 962\u2013970, https:\/\/doi.org\/10.1182\/blood-2012-05-431429 (2013).","journal-title":"Blood"},{"key":"34199_CR15","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1038\/sj.onc.1205629","volume":"21","author":"CB Hertel","year":"2002","unstructured":"Hertel, C. B., Zhou, X. G., Hamilton-Dutoit, S. J. & Junker, S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin\/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21, 4908\u20134920, https:\/\/doi.org\/10.1038\/sj.onc.1205629 (2002).","journal-title":"Oncogene"},{"key":"34199_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/leu.2012.280","volume":"27","author":"V Bohle","year":"2013","unstructured":"Bohle, V., Doring, C., Hansmann, M. L. & Kuppers, R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia 27, 671\u2013679, https:\/\/doi.org\/10.1038\/leu.2012.280 (2013).","journal-title":"Leukemia"},{"key":"34199_CR17","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2011-09-381905","volume":"119","author":"L Xie","year":"2012","unstructured":"Xie, L. et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 119, 3503\u20133511, https:\/\/doi.org\/10.1182\/blood-2011-09-381905 (2012).","journal-title":"Blood"},{"key":"34199_CR18","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","volume":"21","author":"S Mathas","year":"2002","unstructured":"Mathas, S. et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. Embo J 21, 4104\u20134113 (2002).","journal-title":"Embo J"},{"key":"34199_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0002-9440(10)63690-5","volume":"163","author":"M Watanabe","year":"2003","unstructured":"Watanabe, M. et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 163, 633\u2013641 (2003).","journal-title":"Am J Pathol"},{"key":"34199_CR20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/modpathol.3800419","volume":"18","author":"GZ Rassidakis","year":"2005","unstructured":"Rassidakis, G. Z. et al. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 18, 1365\u20131370 (2005).","journal-title":"Mod Pathol"},{"key":"34199_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.humpath.2013.10.024","volume":"45","author":"V Leventaki","year":"2014","unstructured":"Leventaki, V. et al. c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma. Hum Pathol 45, 565\u2013572, https:\/\/doi.org\/10.1016\/j.humpath.2013.10.024 (2014).","journal-title":"Hum Pathol"},{"key":"34199_CR22","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1182\/blood-2007-02-071258","volume":"110","author":"PB Staber","year":"2007","unstructured":"Staber, P. B. et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1\/2 and JunB translation via mTOR signaling. Blood 110, 3374\u20133383 (2007).","journal-title":"Blood"},{"key":"34199_CR23","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1182\/blood-2006-11-059451","volume":"110","author":"V Leventaki","year":"2007","unstructured":"Leventaki, V. et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK\/cJun signaling in anaplastic large-cell lymphoma. Blood 110, 1621\u20131630 (2007).","journal-title":"Blood"},{"key":"34199_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/01.pas.0000213412.25935.e4","volume":"31","author":"E Drakos","year":"2007","unstructured":"Drakos, E. et al. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders. Am J Surg Pathol 31, 447\u2013453 (2007).","journal-title":"Am J Surg Pathol"},{"key":"34199_CR25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1182\/blood-2002-08-2434","volume":"101","author":"X Mao","year":"2003","unstructured":"Mao, X. et al. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101, 1513\u20131519 (2003).","journal-title":"Blood"},{"key":"34199_CR26","doi-asserted-by":"publisher","first-page":"E131","DOI":"10.1038\/ncb0502-e131","volume":"4","author":"E Shaulian","year":"2002","unstructured":"Shaulian, E. & Karin, M. AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131\u2013136 (2002).","journal-title":"Nat Cell Biol"},{"key":"34199_CR27","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/sj.onc.1204383","volume":"20","author":"E Shaulian","year":"2001","unstructured":"Shaulian, E. & Karin, M. AP-1 in cell proliferation and survival. Oncogene 20, 2390\u20132400 (2001).","journal-title":"Oncogene"},{"key":"34199_CR28","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/sj.onc.1204385","volume":"20","author":"Y Chinenov","year":"2001","unstructured":"Chinenov, Y. & Kerppola, T. K. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 20, 2438\u20132452 (2001).","journal-title":"Oncogene"},{"key":"34199_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.0105-2896.2005.00332.x","volume":"208","author":"EF Wagner","year":"2005","unstructured":"Wagner, E. F. & Eferl, R. Fos\/AP-1 proteins in bone and the immune system. Immunol Rev 208, 126\u2013140, https:\/\/doi.org\/10.1111\/j.0105-2896.2005.00332.x (2005).","journal-title":"Immunol Rev"},{"key":"34199_CR30","doi-asserted-by":"publisher","first-page":"7628","DOI":"10.1158\/0008-5472.CAN-05-0925","volume":"65","author":"M Watanabe","year":"2005","unstructured":"Watanabe, M. et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1\/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 65, 7628\u20137634 (2005).","journal-title":"Cancer Res"},{"key":"34199_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.203","author":"A Lollies","year":"2017","unstructured":"Lollies, A. et al. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma. Leukemia. https:\/\/doi.org\/10.1038\/leu.2017.203 (2017).","journal-title":"Leukemia"},{"key":"34199_CR32","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18, 1611\u20131618, https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1942 (2012).","journal-title":"Clin Cancer Res"},{"key":"34199_CR33","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1073\/pnas.0706017104","volume":"104","author":"P Juszczynski","year":"2007","unstructured":"Juszczynski, P. et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104, 13134\u201313139, https:\/\/doi.org\/10.1073\/pnas.0706017104 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"34199_CR34","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2014-05-576140","volume":"124","author":"CW Fhu","year":"2014","unstructured":"Fhu, C. W. et al. Reed-Sternberg cell-derived lymphotoxin-alpha activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. Blood 124, 2973\u20132982, https:\/\/doi.org\/10.1182\/blood-2014-05-576140 (2014).","journal-title":"Blood"},{"key":"34199_CR35","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/MMBR.00025-06","volume":"70","author":"MA Bogoyevitch","year":"2006","unstructured":"Bogoyevitch, M. A. & Kobe, B. Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiology and molecular biology reviews: MMBR 70, 1061\u20131095, https:\/\/doi.org\/10.1128\/MMBR.00025-06 (2006).","journal-title":"Microbiology and molecular biology reviews: MMBR"},{"key":"34199_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 297\u2013315, https:\/\/doi.org\/10.1042\/BJ20070797 (2007).","journal-title":"Biochem J"},{"key":"34199_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10428199309148499","volume":"9","author":"HG Drexler","year":"1993","unstructured":"Drexler, H. G. Recent results on the biology of Hodgkin and Reed-Sternberg cells. II Continuous cell lines. Leukemia & lymphoma 9, 1\u201325, https:\/\/doi.org\/10.3109\/10428199309148499 (1993).","journal-title":"Leukemia & lymphoma"},{"key":"34199_CR38","doi-asserted-by":"crossref","unstructured":"Solovei, I., Schermelleh, L., Albiez, H. & Cremer, T. In Cell Biology (Third Edition) (ed. Celis, J. E.) 291\u2013299 (Academic Press, 2006).","DOI":"10.1016\/B978-012164730-8\/50036-8"},{"key":"34199_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. Journal of cellular physiology 182, 311\u2013322, https:\/\/doi.org\/10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 (2000).","journal-title":"Journal of cellular physiology"},{"key":"34199_CR40","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/0008-5472.CAN-16-0707","volume":"77","author":"M Sobecki","year":"2017","unstructured":"Sobecki, M. et al. Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. Cancer Res 77, 2722\u20132734, https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0707 (2017).","journal-title":"Cancer Res"},{"key":"34199_CR41","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/bjh.13079","volume":"167","author":"V Atsaves","year":"2014","unstructured":"Atsaves, V. et al. The oncogenic JUNB\/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol 167, 514\u2013523, https:\/\/doi.org\/10.1111\/bjh.13079 (2014).","journal-title":"Br J Haematol"},{"key":"34199_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/MCB.18.1.629","volume":"18","author":"AB Niculescu 3rd","year":"1998","unstructured":"Niculescu, A. B. 3rd. et al. Effects of p21(Cip1\/Waf1) at both the G1\/S and the G2\/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18, 629\u2013643 (1998).","journal-title":"Mol Cell Biol"},{"key":"34199_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(95)90039-X","volume":"82","author":"C Deng","year":"1995","unstructured":"Deng, C., Zhang, P., Harper, J. W., Elledge, S. J. & Leder, P. Mice lacking p21CIP1\/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675\u2013684 (1995).","journal-title":"Cell"},{"key":"34199_CR44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/377552a0","volume":"377","author":"J Brugarolas","year":"1995","unstructured":"Brugarolas, J. et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552\u2013557, https:\/\/doi.org\/10.1038\/377552a0 (1995).","journal-title":"Nature"},{"key":"34199_CR45","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc2347","volume":"8","author":"IM Chu","year":"2008","unstructured":"Chu, I. M., Hengst, L. & Slingerland, J. M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8, 253\u2013267, https:\/\/doi.org\/10.1038\/nrc2347 (2008).","journal-title":"Nat Rev Cancer"},{"key":"34199_CR46","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/path.2958","volume":"225","author":"JH Gibcus","year":"2011","unstructured":"Gibcus, J. H. et al. MiR-17\/106b seed family regulates p21 in Hodgkin\u2019s lymphoma. The Journal of pathology 225, 609\u2013617, https:\/\/doi.org\/10.1002\/path.2958 (2011).","journal-title":"The Journal of pathology"},{"key":"34199_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tcb.2011.10.004","volume":"22","author":"NG Starostina","year":"2012","unstructured":"Starostina, N. G. & Kipreos, E. T. Multiple degradation pathways regulate versatile CIP\/KIP CDK inhibitors. Trends Cell Biol 22, 33\u201341, https:\/\/doi.org\/10.1016\/j.tcb.2011.10.004 (2012).","journal-title":"Trends Cell Biol"},{"key":"34199_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3727\/096504012X13285365944292","volume":"19","author":"M Watanabe","year":"2011","unstructured":"Watanabe, M. et al. Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1\/2 pathway in Hodgkin lymphoma cell lines. Oncology research 19, 463\u2013469 (2011).","journal-title":"Oncology research"},{"key":"34199_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-199","volume":"13","author":"JD Pearson","year":"2014","unstructured":"Pearson, J. D. et al. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs. Molecular cancer 13, 199, https:\/\/doi.org\/10.1186\/1476-4598-13-199 (2014).","journal-title":"Molecular cancer"},{"key":"34199_CR50","unstructured":"MISSION\u00ae shRNA Plasmid Control Vectors. Sigma-Aldrich Technical Bulletin,<https:\/\/www.sigmaaldrich.com\/content\/dam\/sigma-aldrich\/docs\/Sigma\/Bulletin\/shc002bul.pdf>(2012)."},{"key":"34199_CR51","doi-asserted-by":"publisher","first-page":"34133","DOI":"10.1074\/jbc.M507831200","volume":"280","author":"RJ Ingham","year":"2005","unstructured":"Ingham, R. J. et al. The Epstein-Barr Virus Protein, Latent Membrane Protein 2A, Co-opts Tyrosine Kinases Used by the T Cell Receptor. J Biol Chem 280, 34133\u201334142 (2005).","journal-title":"J Biol Chem"},{"key":"34199_CR52","first-page":"75","volume":"28","author":"A Korzynska","year":"2008","unstructured":"Korzynska, A. & Zychowicz, M. A Method of Estimation of the Cell Doubling Time on Basis of the Cell Culture MonitoringData. Biocybernetics and Biomedical Engineering 28, 75\u201382 (2008).","journal-title":"Biocybernetics and Biomedical Engineering"},{"key":"34199_CR53","doi-asserted-by":"publisher","first-page":"e18556","DOI":"10.1371\/journal.pone.0018556","volume":"6","author":"JH Kim","year":"2011","unstructured":"Kim, J. H. et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PloS one 6, e18556, https:\/\/doi.org\/10.1371\/journal.pone.0018556 (2011).","journal-title":"PloS one"},{"key":"34199_CR54","first-page":"124","volume":"4","author":"JD Pearson","year":"2011","unstructured":"Pearson, J. D., Lee, J. K., Bacani, J. T., Lai, R. & Ingham, R. J. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma. Int J Clin Exp Pathol 4, 124\u2013133 (2011).","journal-title":"Int J Clin Exp Pathol"},{"key":"34199_CR55","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408, https:\/\/doi.org\/10.1006\/meth.2001.1262 (2001).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34199-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T10:53:17Z","timestamp":1671619997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-34199-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["34199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-34199-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16019"}}